Here are relevant reports on : oncology-diagnostics-market
-
Endoscopic Ultrasonography (EUS) Market by Product (Endoscopes, Ultrasound Processors, Ultrasound Needles, Probes), Type (Diagnostic, Therapeutic), Application (Oncology, GI, End User (Hospitals, Ambulatory Surgical Center) - Global Forecast to 2029
The global endoscopic ultrasonography market, valued at US$1.28 billion in 2023, stood at US$1.37 billion in 2024 and is projected to advance at a resilient CAGR of 7.1% from 2024 to 2029, culminating in a forecasted valuation of US$1.93 billion by the end of the period. The growth in the endoscopic ultrasonography market can be attributed to the factors, including increasing investments, funds, and grants by governments and other organizations, rising focus of hospitals to expand endoscopic ultrasonography units and bring advancements in endoscopic ultrasonography technologies.
- Published: February 2025
- Price: $ 4950
- TOC Available:
-
High Potency APIs Market / HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) & Region - Global Forecast to 2027
The global high potency APIs market growth is primed to transition from $24.5 billion in 2022 to $39.6 billion by 2027, showcasing a strong CAGR of 10.1%. This growth is driven by increasing demand for oncology drugs, advancements in HPAPI manufacturing technologies, and the rising focus on precision medicine.
- Published: May 2022
- Price: $ 4950
- TOC Available:
-
Drug Discovery Technologies Market by Product (Instruments, Reagents, Software), Technology (HTS, NGS, PCR, AI-based, Lab-on-chip), Process (Target Identification, Validation, Lead Optimization), Therapeutic Area (Oncology, CVD) - Global Forecast to 2030
The Drug Discovery Technologies market, valued at US$28.61 billion in 2024, stood at US$30.58 billion in 2025 and is projected to advance at a resilient CAGR of 11.0% from 2025 to 2030, culminating in a forecasted valuation of US$51.51 billion by the end of the period. The growth of the drug discovery technologies market is driven by the broader use of advanced screening platforms and rising demand for biologics, cell and gene therapies, and RNA-based drugs.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Positron Emission Tomography Market by Product (Standalone PET Systems, PET/CT Systems, PET/MRI Systems), Application (Oncology, Cardiology, Neurology), End User (Hospitals & Surgical Centers, Diagnostic & Imaging Clinics) & Region - Global Forecasts to 2028
The global positron emission tomography market, valued at US$2.3 billion in 2022, stood at US$2.5 billion in 2023 and is projected to advance at a resilient CAGR of 6.6% from 2023 to 2028, culminating in a forecasted valuation of US$3.5 billion by the end of the period. Technological advancements and new product launches in the radiopharmaceuticals and PET systems, coupled with a growing target patient population, are the key factors driving the adoption of PET systems globally.
- Published: June 2023
- Price: $ 4950
- TOC Available:
-
Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035
The global biosimilars market, valued at US$32.75 billion in 2024, stood at US$35.04 billion in 2025 and is projected to advance at a resilient CAGR of 7.5% from 2025 to 2035, culminating in a forecasted valuation of US$72.29 billion by the end of the period. This growth is driven by several key factors, including a rising number of regulatory approvals and product launches, the patent expiries of major biologics, and the increasing prevalence of chronic diseases that require effective and affordable treatment options.
- Published: June 2025
- Price: $ 4950
- TOC Available:
-
Active Pharmaceutical Ingredients (API) Market by type (Innovative, Generic), Synthesis (synthetic, biotech), Potency (HPAPI), Product (mAbs, hormones), Drug (OTC, Rx), Application (Diabetes, Oncology), Competitive landscape - Global forecast to 2030
The global active pharmaceutical ingredient market, valued at US$136.22 billion in 2024, stood at US$144.20 billion in 2025 and is projected to advance at a resilient CAGR of 6.6% from 2024 to 2030, culminating in a forecasted valuation of US$198.39 billion by the end of the period. The growth of the active pharmaceutical ingredients market is driven by the surge in demand for complex APIs, such as high-potency API, peptides, oligonucleotides, and increasing government incentives and supply chain reshoring.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Nuclear Imaging Equipment Market by Product (SPECT (Hybrid SPECT, Standalone SPECT), Hybrid PET, & Planar Scintigraphy), Application (Oncology, Cardiology & Neurology) & End user (Hospitals, Imaging Centers) & Region - Global Forecast to 2025
The global nuclear imaging equipment market growth is primed to transition from $2.6 billion in 2020 to $3.4 billion by 2025, showcasing a strong CAGR of 7.4%. The growth in this market is mainly driven by the the shift from standalone to hybrid modalities, advances in radiotracers, the increasing focus on personalized medicine, investments through public-private partnerships to modernize diagnostic imaging centers, and the increasing incidence and prevalence of cancer and cardiac ailments.
- Published: February 2021
- Price: $ 4950
- TOC Available:
-
Picture Archiving and Communications Systems/ PACS Systems Market– By Components (Software and Hardware), Delivery Mode & Imaging Types [Cardiology PACS, Oncology PACS, Dental PACS] - Global Trends, Competitor Analysis & Forecasts To 2017
PACS stands for picture archiving and communication system. PACS has helped in reducing the physical and time barriers associated with traditional film-based image retrieval, distribution, and display. PACS is finding widespread application in hospitals and clinics as it eliminates the need of maintaining hard copies of images and replaces them with digital storage. Market for PACS solutions is growing at a faster rate as healthcare providers are finding it difficult to remain competitive without PACS. Most of the players who are offering PACS to larger hospitals are now targeting small hospitals and diagnostic centers. The Global PACS market is estimated at $2.5 Billion in 2010 and is expected to grow at a CAGR of 14.9% and reach $5 Billion.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Clinical Trial Services Market by Type (Laboratory, Monitoring, Recruitment, PV, Data Management), Phase (I, II, III), Therapy (Oncology, Neurology, Dermatology, CVD), Modality (Biologics, Devices), Delivery Model (FSP, Hybrid) - Global Forecast to 2030
The global Clinical Trial Services market, valued at US$60.76 billion in 2024, stood at US$66.59 billion in 2025 and is projected to advance at a resilient CAGR of 8.9% from 2025 to 2030, culminating in a forecasted valuation of US$101.86 billion by the end of the period. Factors such as the growing focus on patient-centric clinical trials such as Decentralized Clinical trials (DCTs) and the increasing number of clinical trials for precision/personalized medicines are supporting the growth of this market.
- Published: March 2025
- Price: $ 4950
- TOC Available:
-
North America Injectable Drug Delivery Market – by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] – Forecasts to 2017
The North American injectable drug delivery technologies market was valued at $9.3 billion in 2012; it is expected to reach $16.6 billion by 2017 at a CAGR of 12.3% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices.
- Published: April 2013
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
